Medicine (Jul 2023)

Safety and Current Status of the COVID-19 Vaccine among Patients with Breast cancer: A Cross-Sectional Study from China

  • Shaohua Zhang,
  • Jianbin Li,
  • Ruonan Xu,
  • Qianjun Chen,
  • Gang Sun,
  • Ying Lin,
  • Feng Jin,
  • Xinlan Liu,
  • Zhimin Fan,
  • Yiding Chen,
  • Yali Cao,
  • Xinzheng Li,
  • Jianyun Nie,
  • Guiying Xu,
  • Xiaojia Wang,
  • Yuee Teng,
  • Tao Sun,
  • Hong Liu,
  • Jing Luo,
  • Cuizhi Geng,
  • Man Li,
  • Ting Luo,
  • Yinhua Liu,
  • Fu-Sheng Wang,
  • Zefei Jiang,
  • Wang Haijuan

DOI
https://doi.org/10.1097/ID9.0000000000000090
Journal volume & issue
Vol. 3, no. 3
pp. 127 – 131

Abstract

Read online

Abstract. In this study, we aimed to explore the safety and vaccination coverage data of Chinese patients with breast cancer receiving coronavirus disease 2019 (COVID-19) vaccination. The patients were recruited from 41 hospitals across 20 Chinese provinces. The vaccination coverage was approximately 22.4%, and the frequency of total adverse events was 13.3% after the first dose and 9.9% after the second dose. The most frequent adverse reaction within 14 days of the first dose was local pain (5.7%). Unvaccinated patients were very likely to reject the vaccine rather than be hesitant in patients with old age (odds ratio [OR], 1.238; 95% confidence interval [CI], 1.101–1.391), chronic disease history (OR, 1.189; 95% CI, 1.057–1.337), and cancer relapse (OR, 1.398; 95% CI, 1.233–1.585). Of the unvaccinated patients with breast cancer, 54.1% opted to receive COVID-19 vaccines if more data were available. Considering the safety but low vaccination coverage for breast cancer, increased positive attitudes and acceptance toward COVID-19 vaccines are important.